{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"vip-muscle-loss","title":"VIP for Muscle Loss: Preclinical Signals on Vasoactive Intestinal Peptide","body":"## What's breaking down\nMuscle loss, or atrophy, occurs when breakdown outruns repair in skeletal muscle tissue. Layers include disuse from reduced activity, age-related sarcopenia with declining anabolic signals, inflammation that promotes protein breakdown via pathways like MuRF1, and impaired blood flow or oxygenation that limits nutrient delivery and waste removal. In disuse or ischemia models, contractile force drops as muscle fibers shrink. VIP sits in the immune and autonomic layer because it modulates inflammation and smooth muscle tone in vessels, potentially supporting repair signals rather than suppressing symptoms directly.\n\n## Why VIP might help you\nIf your muscle loss involves an immune or autonomic component, such as chronic low-grade inflammation accelerating protein breakdown or autonomic imbalance affecting blood flow, VIP is discussed for its studied effects on tissue repair pathways. Step one: VIP activates VPAC2 receptors, which in lab models reduced skeletal muscle mass loss during disuse. Step two: This receptor activation preserved force generation, pointing to a direct influence on muscle maintenance rather than masking fatigue. Step three: In reperfusion settings after ischemia, VIP raised contractile force and tissue oxygen levels above baseline in rat muscle. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain. If autonomic regulation of blood vessels limits delivery during recovery, VIP's vasodilatory actions could fit there too.\n\n## How these fit together\nSingle-compound focus — VIP targets the immune/autonomic layer. If your profile includes other degeneration layers like mitochondrial decline or hormonal shifts, this peptide addresses only the immune/autonomic slice without overlapping other mechanisms.\n\n## What the evidence actually shows\nA 2005 study activated VPAC2 receptors with VIP agonists in rodent disuse models and found reduced loss of skeletal muscle mass and force (preclinical). A 1997 rat study on ischemic-reperfused skeletal muscle showed VIP given at reperfusion onset increased contractile force and oxygenation beyond baseline levels (preclinical, animal). VIP knockout mice displayed lower body weight, lower fat mass, and higher lean mass percentage compared to wild-type (preclinical). No human clinical trials specifically testing VIP administration for muscle loss or sarcopenia appear in available records. All direct muscle-related data remain at the animal level.\n\n## What scientists say\nResearchers note VPAC2 activation as a potential brake on disuse atrophy in skeletal muscle, based on the 2005 receptor study. Broader VIP reviews highlight its roles in smooth muscle relaxation, anti-inflammatory signaling, and tissue perfusion, but muscle-specific applications stay limited to preclinical observations. Human data on VIP focus more on gut motility, immune modulation in inflammatory conditions, and cardiovascular effects rather than sarcopenia.\n\n## What people say on Reddit\nAnecdotal reports mention VIP in contexts of chronic inflammation, ME/CFS recovery, or training pumps via vasodilation, with some users pairing it with other compounds for muscle-related fatigue or recovery. Posts note patience required for effects and discuss it alongside immune or gut issues rather than direct muscle building. No widespread claims of dramatic muscle gain from VIP alone surface in searches; discussions remain exploratory and tied to broader health stacks.\n\n## What people say on X\nPublic posts on X show minimal specific discussion of VIP for muscle loss. Scattered mentions cover its general vasodilatory or anti-inflammatory properties, but no detailed user experiences or before-after reports tied to sarcopenia or atrophy appear in recent searches.\n\n## What we do not know\nHuman trials measuring muscle mass, strength, or function after VIP administration are absent. Long-term effects on lean mass preservation, optimal delivery methods, and interactions with exercise or nutrition remain untested in people. Whether VIP deficiency or excess correlates with sarcopenia progression in humans is unknown. Translation from rat disuse or ischemia models to human age-related or disease-driven muscle loss has not been validated.\n\n## Safety and limits\nVIP research in humans centers on its endogenous roles and short-term physiological effects; no dedicated safety database for repeated use in muscle loss contexts exists. Animal data show receptor-specific actions without broad toxicity signals in the cited studies, but individual responses vary. Evidence grading places all muscle-related findings in the preclinical tier, with anecdotal reports at the lowest tier. Always consult primary sources and professionals for personal decisions.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/vip-muscle-loss/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Activation of VPAC2 receptors with VIP agonists reduced loss of skeletal muscle mass and force in rodent disuse models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Direct link to muscle preservation mechanism in lab setting.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"VIP administration at reperfusion onset increased contractile force and tissue oxygenation in ischemic-reperfused rat skeletal muscle.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Shows potential repair support in ischemia model.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"VIP knockout mice had lower body weight, lower fat mass, and increased lean mass percentage.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Indicates endogenous VIP role in body composition.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No human clinical trials test VIP for muscle loss or sarcopenia.","section":"What we do not know","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Clarifies evidence gap for readers.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users discuss VIP anecdotally for inflammation recovery or training pumps but not direct muscle gain.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s5"],"source_status":"sourced","why_material":"Separates user reports from data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/15649881/","title":"Activation of the vasoactive intestinal peptide 2 receptor modulates skeletal muscle mass and force","quote":"activation of VPAC2R, but not VPAC1R, reduced the loss of skeletal muscle mass and force during conditions of skeletal muscle disuse","summary":"2005 rodent study on VPAC2 activation and muscle preservation.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:28:03.811Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"3111b5552a2752892fb9b82c4c30848f5e72c8eef17cf6ef3497166eeb354e05"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/9149300/","title":"Ischemic-reperfused rat skeletal muscle: the effect of vasoactive intestinal peptide","quote":"VIP administration at the onset of reperfusion significantly increased skeletal muscle contractile force and tissue oxygenation even higher than baseline","summary":"1997 rat ischemia-reperfusion study with VIP.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:28:03.811Z","link_status":"ok","quote_status":"verified","prev":"3111b5552a2752892fb9b82c4c30848f5e72c8eef17cf6ef3497166eeb354e05","hash":"3ba4cff0b6f683143275cc76bdc8a0fe276a307ea41d3c7c01722ce54d78a240"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/27535909/","title":"Vasoactive intestinal peptide-deficient mice show altered body composition","quote":"VIP−/− mice showed a lower body weight and fat mass and an increased lean mass","summary":"Mouse knockout study on VIP and lean mass.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:28:03.811Z","link_status":"ok","quote_status":"unverified","prev":"3ba4cff0b6f683143275cc76bdc8a0fe276a307ea41d3c7c01722ce54d78a240","hash":"b8730b4ebfff780f7d940b4a1e847a8ed2e0b5d0f15091cd2fd61712aa6d38ce"},{"id":"s4","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6743256/","title":"Recent advances in vasoactive intestinal peptide physiology","quote":"VIP has multiple physiological and pathological effects","summary":"2019 review confirming lack of muscle-specific human trials.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:28:03.811Z","link_status":"ok","quote_status":"unverified","prev":"b8730b4ebfff780f7d940b4a1e847a8ed2e0b5d0f15091cd2fd61712aa6d38ce","hash":"800dff28eae0c90a4f2adfe84701fd1a5cffe07147800015fde0e1811beb1b13"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/Biohack_Blueprint/comments/1u31ihv/the_peptide_nobody_talks_about_but_everyone/","title":"The peptide nobody talks about but everyone should: VIP","quote":"Mold illness and chronic inflammation does not get the same hype as fat loss or muscle growth. Two, VIP requires patience.","summary":"Anecdotal Reddit discussion on VIP uses.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:28:03.811Z","link_status":"ok","quote_status":"unverified","prev":"800dff28eae0c90a4f2adfe84701fd1a5cffe07147800015fde0e1811beb1b13","hash":"53091e66d70c3d8574697008c1e145422d7f58c47c03fd736a54001244801f13"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:28:05.298Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"VIP for Muscle Loss: Preclinical Signals on Vasoactive Intestinal Peptide","register":"source_ledger","body":"## What's breaking down\nMuscle loss, or atrophy, occurs when breakdown outruns repair in skeletal muscle tissue. Layers include disuse from reduced activity, age-related sarcopenia with declining anabolic signals, inflammation that promotes protein breakdown via pathways like MuRF1, and impaired blood flow or oxygenation that limits nutrient delivery and waste removal. In disuse or ischemia models, contractile force drops as muscle fibers shrink. VIP sits in the immune and autonomic layer because it modulates inflammation and smooth muscle tone in vessels, potentially supporting repair signals rather than suppressing symptoms directly.\n\n## Why VIP might help you\nIf your muscle loss involves an immune or autonomic component, such as chronic low-grade inflammation accelerating protein breakdown or autonomic imbalance affecting blood flow, VIP is discussed for its studied effects on tissue repair pathways. Step one: VIP activates VPAC2 receptors, which in lab models reduced skeletal muscle mass loss during disuse. Step two: This receptor activation preserved force generation, pointing to a direct influence on muscle maintenance rather than masking fatigue. Step three: In reperfusion settings after ischemia, VIP raised contractile force and tissue oxygen levels above baseline in rat muscle. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain. If autonomic regulation of blood vessels limits delivery during recovery, VIP's vasodilatory actions could fit there too.\n\n## How these fit together\nSingle-compound focus — VIP targets the immune/autonomic layer. If your profile includes other degeneration layers like mitochondrial decline or hormonal shifts, this peptide addresses only the immune/autonomic slice without overlapping other mechanisms.\n\n## What the evidence actually shows\nA 2005 study activated VPAC2 receptors with VIP agonists in rodent disuse models and found reduced loss of skeletal muscle mass and force (preclinical). A 1997 rat study on ischemic-reperfused skeletal muscle showed VIP given at reperfusion onset increased contractile force and oxygenation beyond baseline levels (preclinical, animal). VIP knockout mice displayed lower body weight, lower fat mass, and higher lean mass percentage compared to wild-type (preclinical). No human clinical trials specifically testing VIP administration for muscle loss or sarcopenia appear in available records. All direct muscle-related data remain at the animal level.\n\n## What scientists say\nResearchers note VPAC2 activation as a potential brake on disuse atrophy in skeletal muscle, based on the 2005 receptor study. Broader VIP reviews highlight its roles in smooth muscle relaxation, anti-inflammatory signaling, and tissue perfusion, but muscle-specific applications stay limited to preclinical observations. Human data on VIP focus more on gut motility, immune modulation in inflammatory conditions, and cardiovascular effects rather than sarcopenia.\n\n## What people say on Reddit\nAnecdotal reports mention VIP in contexts of chronic inflammation, ME/CFS recovery, or training pumps via vasodilation, with some users pairing it with other compounds for muscle-related fatigue or recovery. Posts note patience required for effects and discuss it alongside immune or gut issues rather than direct muscle building. No widespread claims of dramatic muscle gain from VIP alone surface in searches; discussions remain exploratory and tied to broader health stacks.\n\n## What people say on X\nPublic posts on X show minimal specific discussion of VIP for muscle loss. Scattered mentions cover its general vasodilatory or anti-inflammatory properties, but no detailed user experiences or before-after reports tied to sarcopenia or atrophy appear in recent searches.\n\n## What we do not know\nHuman trials measuring muscle mass, strength, or function after VIP administration are absent. Long-term effects on lean mass preservation, optimal delivery methods, and interactions with exercise or nutrition remain untested in people. Whether VIP deficiency or excess correlates with sarcopenia progression in humans is unknown. Translation from rat disuse or ischemia models to human age-related or disease-driven muscle loss has not been validated.\n\n## Safety and limits\nVIP research in humans centers on its endogenous roles and short-term physiological effects; no dedicated safety database for repeated use in muscle loss contexts exists. Animal data show receptor-specific actions without broad toxicity signals in the cited studies, but individual responses vary. Evidence grading places all muscle-related findings in the preclinical tier, with anecdotal reports at the lowest tier. Always consult primary sources and professionals for personal decisions.","claims":[{"id":"c1","text":"Activation of VPAC2 receptors with VIP agonists reduced loss of skeletal muscle mass and force in rodent disuse models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Direct link to muscle preservation mechanism in lab setting.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"VIP administration at reperfusion onset increased contractile force and tissue oxygenation in ischemic-reperfused rat skeletal muscle.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Shows potential repair support in ischemia model.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"VIP knockout mice had lower body weight, lower fat mass, and increased lean mass percentage.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Indicates endogenous VIP role in body composition.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No human clinical trials test VIP for muscle loss or sarcopenia.","section":"What we do not know","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Clarifies evidence gap for readers.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users discuss VIP anecdotally for inflammation recovery or training pumps but not direct muscle gain.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s5"],"source_status":"sourced","why_material":"Separates user reports from data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/15649881/","title":"Activation of the vasoactive intestinal peptide 2 receptor modulates skeletal muscle mass and force","quote":"activation of VPAC2R, but not VPAC1R, reduced the loss of skeletal muscle mass and force during conditions of skeletal muscle disuse","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/9149300/","title":"Ischemic-reperfused rat skeletal muscle: the effect of vasoactive intestinal peptide","quote":"VIP administration at the onset of reperfusion significantly increased skeletal muscle contractile force and tissue oxygenation even higher than baseline","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/27535909/","title":"Vasoactive intestinal peptide-deficient mice show altered body composition","quote":"VIP−/− mice showed a lower body weight and fat mass and an increased lean mass","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6743256/","title":"Recent advances in vasoactive intestinal peptide physiology","quote":"VIP has multiple physiological and pathological effects","link_status":"ok","quote_status":"unverified"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/Biohack_Blueprint/comments/1u31ihv/the_peptide_nobody_talks_about_but_everyone/","title":"The peptide nobody talks about but everyone should: VIP","quote":"Mold illness and chronic inflammation does not get the same hype as fat loss or muscle growth. Two, VIP requires patience.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":14739,"tokens_out":2818,"cost":0.02546875,"prev_hash":"genesis","hash":"ab3c7fcfa3c02e16ee2de137171e857d44cceeafae49b734f25be3c8d114cc04"}],"provenance":[{"ts":"2026-06-29T22:28:05.298Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Vip for Muscle Loss\nSlug: vip-muscle-loss\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"vip\",\"name\":\"VIP\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"vip\",\"name\":\"VIP\",\"section_title\":\"Why VIP might help you\",\"layer\":\"immune / autonomic\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **VIP** → immune / autonomic\",\"section_headings\":[\"What's breaking down\",\"Why VIP might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains / drug_chains.\",\"weight","response":"{\n  \"slug\": \"vip-muscle-loss\",\n  \"title\": \"VIP for Muscle Loss: Preclinical Signals on Vasoactive Intestinal Peptide\",\n  \"body\": \"## What's breaking down\\nMuscle loss, or atrophy, occurs when breakdown outruns repair in skeletal muscle tissue. Layers include disuse from reduced activity, age-related sarcopenia with declining anabolic signals, inflammation that promotes protein breakdown via pathways like MuRF1, and impaired blood flow or oxygenation that limits nutrient delivery and waste removal. In disuse or ischemia models, contractile force drops as muscle fibers shrink. VIP sits in the immune and autonomic layer because it modulates inflammation and smooth muscle tone in vessels, potentially supporting repair signals rather than suppressing symptoms directly.\\n\\n## Why VIP might help you\\nIf your muscle loss involves an immune or autonomic component, such as chronic low-grade inflammation accelerating protein breakdown or autonomic imbalance affecting blood flow, VIP is discussed for its studied effects on tissue repair pathways. Step one: VIP activates VPAC2 receptors, which in lab models reduced skeletal muscle mass loss during disuse. Step two: This receptor activation preserved force generation, pointing to a direct influence on muscle maintenance rather than masking fatigue. Step three: In reperfusion settings after ischemia, VIP raised contractile force and tissue oxygen levels above baseline in rat muscle. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain. If autonomic regulation of blood vessels limits delivery during recovery, VIP's vasodilatory actions could fit there too.\\n\\n## How these fit together\\nSingle-compound focus — VIP targets the immune/autonomic layer. If your profile includes other degeneration layers like mitochondrial decline or hormonal shifts, this peptide addresses only the immune/autonomic slice without overlapping other mechanisms.\\n\\n## What t","tokens_in":14739,"tokens_out":2818,"cost":0,"prev":"genesis","hash":"51f30a41dda599e0554f83234ddc244f754f4b3203859afc044bff5cee47c01e"},{"ts":"2026-07-17T02:43:25.271Z","model":"owner","action":"voxel_divide","prompt":"","input":"vip-muscle-loss","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"51f30a41dda599e0554f83234ddc244f754f4b3203859afc044bff5cee47c01e","hash":"bf5b64df9799413c34643e9172e1586e7f01272be66e3a35710a6938096f8366"}],"energy":{"passes":2,"tokens_in":14739,"tokens_out":2818,"tokens_total":17557,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"bf5b64df9799413c34643e9172e1586e7f01272be66e3a35710a6938096f8366"},"posted_at":"2026-06-29T21:33:50.979Z","created_at":"2026-06-29T21:33:50.979Z","updated_at":"2026-07-17T02:43:25.271Z","machine":{"shape":"article.machine/v1","slug":"vip-muscle-loss","kind":"article","read":{"human":"https://miscsubjects.com/a/vip-muscle-loss","json":"https://miscsubjects.com/api/articles/vip-muscle-loss","bundle":"https://miscsubjects.com/api/articles/vip-muscle-loss/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":5,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/vip-muscle-loss/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=vip-muscle-loss","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-muscle-loss\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-muscle-loss\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/vip-muscle-loss/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"vip-muscle-loss\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/vip-muscle-loss | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/vip-muscle-loss","json":"/api/articles/vip-muscle-loss","markdown":"/api/articles/vip-muscle-loss/bundle?format=markdown","skill":"/api/articles/vip-muscle-loss/skill","topology":"/api/articles/vip-muscle-loss/topology","versions":"/api/articles/vip-muscle-loss/revisions","invocations":"/api/articles/vip-muscle-loss/invocations"},"editorial_review":null,"editorial_audit":{"slug":"vip-muscle-loss","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"fc4921a48d6647a6f29e9a556778f081936aa5e6c2d65d0ed4a300ad2a8a18ec","object":{"object_type":"article-object","identity":{"id":"article:vip-muscle-loss","slug":"vip-muscle-loss","title":"VIP for Muscle Loss: Preclinical Signals on Vasoactive Intestinal Peptide"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/vip-muscle-loss","role":"explain","audience":"human"},"skill":{"route":"/api/articles/vip-muscle-loss/skill","role":"direct behavior","audience":"model","content":"---\nname: vip-muscle-loss\ndescription: Apply the VIP for Muscle Loss: Preclinical Signals on Vasoactive Intestinal Peptide article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# VIP for Muscle Loss: Preclinical Signals on Vasoactive Intestinal Peptide\n\nThis Skill is the behavioral expression of [the canonical article](/a/vip-muscle-loss). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/vip-muscle-loss.\n- Read claims and relationships at /api/articles/vip-muscle-loss/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Muscle loss, or atrophy, occurs when breakdown outruns repair in skeletal muscle tissue. Layers include disuse from reduced activity, age-related sarcopenia with declining anabolic signals, inflammation that promotes pr\n\n## Representations\n\n- Human: /a/vip-muscle-loss\n- JSON: /api/articles/vip-muscle-loss\n- Relationships: /api/articles/vip-muscle-loss/topology\n- History: /api/articles/vip-muscle-loss/revisions\n"},"json":{"route":"/api/articles/vip-muscle-loss","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/vip-muscle-loss/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","vip","muscle","loss"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/vip-muscle-loss/invocations?status=success","failure_events":"/api/articles/vip-muscle-loss/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"vip-muscle-loss","title":"VIP for Muscle Loss: Preclinical Signals on Vasoactive Intestinal Peptide","body":"## What's breaking down\nMuscle loss, or atrophy, occurs when breakdown outruns repair in skeletal muscle tissue. Layers include disuse from reduced activity, age-related sarcopenia with declining anabolic signals, inflammation that promotes protein breakdown via pathways like MuRF1, and impaired blood flow or oxygenation that limits nutrient delivery and waste removal. In disuse or ischemia models, contractile force drops as muscle fibers shrink. VIP sits in the immune and autonomic layer because it modulates inflammation and smooth muscle tone in vessels, potentially supporting repair signals rather than suppressing symptoms directly.\n\n## Why VIP might help you\nIf your muscle loss involves an immune or autonomic component, such as chronic low-grade inflammation accelerating protein breakdown or autonomic imbalance affecting blood flow, VIP is discussed for its studied effects on tissue repair pathways. Step one: VIP activates VPAC2 receptors, which in lab models reduced skeletal muscle mass loss during disuse. Step two: This receptor activation preserved force generation, pointing to a direct influence on muscle maintenance rather than masking fatigue. Step three: In reperfusion settings after ischemia, VIP raised contractile force and tissue oxygen levels above baseline in rat muscle. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain. If autonomic regulation of blood vessels limits delivery during recovery, VIP's vasodilatory actions could fit there too.\n\n## How these fit together\nSingle-compound focus — VIP targets the immune/autonomic layer. If your profile includes other degeneration layers like mitochondrial decline or hormonal shifts, this peptide addresses only the immune/autonomic slice without overlapping other mechanisms.\n\n## What the evidence actually shows\nA 2005 study activated VPAC2 receptors with VIP agonists in rodent disuse models and found reduced loss of skeletal muscle mass and force (preclinical). A 1997 rat study on ischemic-reperfused skeletal muscle showed VIP given at reperfusion onset increased contractile force and oxygenation beyond baseline levels (preclinical, animal). VIP knockout mice displayed lower body weight, lower fat mass, and higher lean mass percentage compared to wild-type (preclinical). No human clinical trials specifically testing VIP administration for muscle loss or sarcopenia appear in available records. All direct muscle-related data remain at the animal level.\n\n## What scientists say\nResearchers note VPAC2 activation as a potential brake on disuse atrophy in skeletal muscle, based on the 2005 receptor study. Broader VIP reviews highlight its roles in smooth muscle relaxation, anti-inflammatory signaling, and tissue perfusion, but muscle-specific applications stay limited to preclinical observations. Human data on VIP focus more on gut motility, immune modulation in inflammatory conditions, and cardiovascular effects rather than sarcopenia.\n\n## What people say on Reddit\nAnecdotal reports mention VIP in contexts of chronic inflammation, ME/CFS recovery, or training pumps via vasodilation, with some users pairing it with other compounds for muscle-related fatigue or recovery. Posts note patience required for effects and discuss it alongside immune or gut issues rather than direct muscle building. No widespread claims of dramatic muscle gain from VIP alone surface in searches; discussions remain exploratory and tied to broader health stacks.\n\n## What people say on X\nPublic posts on X show minimal specific discussion of VIP for muscle loss. Scattered mentions cover its general vasodilatory or anti-inflammatory properties, but no detailed user experiences or before-after reports tied to sarcopenia or atrophy appear in recent searches.\n\n## What we do not know\nHuman trials measuring muscle mass, strength, or function after VIP administration are absent. Long-term effects on lean mass preservation, optimal delivery methods, and interactions with exercise or nutrition remain untested in people. Whether VIP deficiency or excess correlates with sarcopenia progression in humans is unknown. Translation from rat disuse or ischemia models to human age-related or disease-driven muscle loss has not been validated.\n\n## Safety and limits\nVIP research in humans centers on its endogenous roles and short-term physiological effects; no dedicated safety database for repeated use in muscle loss contexts exists. Animal data show receptor-specific actions without broad toxicity signals in the cited studies, but individual responses vary. Evidence grading places all muscle-related findings in the preclinical tier, with anecdotal reports at the lowest tier. Always consult primary sources and professionals for personal decisions.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/vip-muscle-loss/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Activation of VPAC2 receptors with VIP agonists reduced loss of skeletal muscle mass and force in rodent disuse models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Direct link to muscle preservation mechanism in lab setting.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"VIP administration at reperfusion onset increased contractile force and tissue oxygenation in ischemic-reperfused rat skeletal muscle.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Shows potential repair support in ischemia model.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"VIP knockout mice had lower body weight, lower fat mass, and increased lean mass percentage.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Indicates endogenous VIP role in body composition.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No human clinical trials test VIP for muscle loss or sarcopenia.","section":"What we do not know","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Clarifies evidence gap for readers.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users discuss VIP anecdotally for inflammation recovery or training pumps but not direct muscle gain.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s5"],"source_status":"sourced","why_material":"Separates user reports from data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/15649881/","title":"Activation of the vasoactive intestinal peptide 2 receptor modulates skeletal muscle mass and force","quote":"activation of VPAC2R, but not VPAC1R, reduced the loss of skeletal muscle mass and force during conditions of skeletal muscle disuse","summary":"2005 rodent study on VPAC2 activation and muscle preservation.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:28:03.811Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"3111b5552a2752892fb9b82c4c30848f5e72c8eef17cf6ef3497166eeb354e05"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/9149300/","title":"Ischemic-reperfused rat skeletal muscle: the effect of vasoactive intestinal peptide","quote":"VIP administration at the onset of reperfusion significantly increased skeletal muscle contractile force and tissue oxygenation even higher than baseline","summary":"1997 rat ischemia-reperfusion study with VIP.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:28:03.811Z","link_status":"ok","quote_status":"verified","prev":"3111b5552a2752892fb9b82c4c30848f5e72c8eef17cf6ef3497166eeb354e05","hash":"3ba4cff0b6f683143275cc76bdc8a0fe276a307ea41d3c7c01722ce54d78a240"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/27535909/","title":"Vasoactive intestinal peptide-deficient mice show altered body composition","quote":"VIP−/− mice showed a lower body weight and fat mass and an increased lean mass","summary":"Mouse knockout study on VIP and lean mass.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:28:03.811Z","link_status":"ok","quote_status":"unverified","prev":"3ba4cff0b6f683143275cc76bdc8a0fe276a307ea41d3c7c01722ce54d78a240","hash":"b8730b4ebfff780f7d940b4a1e847a8ed2e0b5d0f15091cd2fd61712aa6d38ce"},{"id":"s4","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6743256/","title":"Recent advances in vasoactive intestinal peptide physiology","quote":"VIP has multiple physiological and pathological effects","summary":"2019 review confirming lack of muscle-specific human trials.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:28:03.811Z","link_status":"ok","quote_status":"unverified","prev":"b8730b4ebfff780f7d940b4a1e847a8ed2e0b5d0f15091cd2fd61712aa6d38ce","hash":"800dff28eae0c90a4f2adfe84701fd1a5cffe07147800015fde0e1811beb1b13"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/Biohack_Blueprint/comments/1u31ihv/the_peptide_nobody_talks_about_but_everyone/","title":"The peptide nobody talks about but everyone should: VIP","quote":"Mold illness and chronic inflammation does not get the same hype as fat loss or muscle growth. Two, VIP requires patience.","summary":"Anecdotal Reddit discussion on VIP uses.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:28:03.811Z","link_status":"ok","quote_status":"unverified","prev":"800dff28eae0c90a4f2adfe84701fd1a5cffe07147800015fde0e1811beb1b13","hash":"53091e66d70c3d8574697008c1e145422d7f58c47c03fd736a54001244801f13"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:28:05.298Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"VIP for Muscle Loss: Preclinical Signals on Vasoactive Intestinal Peptide","register":"source_ledger","body":"## What's breaking down\nMuscle loss, or atrophy, occurs when breakdown outruns repair in skeletal muscle tissue. Layers include disuse from reduced activity, age-related sarcopenia with declining anabolic signals, inflammation that promotes protein breakdown via pathways like MuRF1, and impaired blood flow or oxygenation that limits nutrient delivery and waste removal. In disuse or ischemia models, contractile force drops as muscle fibers shrink. VIP sits in the immune and autonomic layer because it modulates inflammation and smooth muscle tone in vessels, potentially supporting repair signals rather than suppressing symptoms directly.\n\n## Why VIP might help you\nIf your muscle loss involves an immune or autonomic component, such as chronic low-grade inflammation accelerating protein breakdown or autonomic imbalance affecting blood flow, VIP is discussed for its studied effects on tissue repair pathways. Step one: VIP activates VPAC2 receptors, which in lab models reduced skeletal muscle mass loss during disuse. Step two: This receptor activation preserved force generation, pointing to a direct influence on muscle maintenance rather than masking fatigue. Step three: In reperfusion settings after ischemia, VIP raised contractile force and tissue oxygen levels above baseline in rat muscle. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain. If autonomic regulation of blood vessels limits delivery during recovery, VIP's vasodilatory actions could fit there too.\n\n## How these fit together\nSingle-compound focus — VIP targets the immune/autonomic layer. If your profile includes other degeneration layers like mitochondrial decline or hormonal shifts, this peptide addresses only the immune/autonomic slice without overlapping other mechanisms.\n\n## What the evidence actually shows\nA 2005 study activated VPAC2 receptors with VIP agonists in rodent disuse models and found reduced loss of skeletal muscle mass and force (preclinical). A 1997 rat study on ischemic-reperfused skeletal muscle showed VIP given at reperfusion onset increased contractile force and oxygenation beyond baseline levels (preclinical, animal). VIP knockout mice displayed lower body weight, lower fat mass, and higher lean mass percentage compared to wild-type (preclinical). No human clinical trials specifically testing VIP administration for muscle loss or sarcopenia appear in available records. All direct muscle-related data remain at the animal level.\n\n## What scientists say\nResearchers note VPAC2 activation as a potential brake on disuse atrophy in skeletal muscle, based on the 2005 receptor study. Broader VIP reviews highlight its roles in smooth muscle relaxation, anti-inflammatory signaling, and tissue perfusion, but muscle-specific applications stay limited to preclinical observations. Human data on VIP focus more on gut motility, immune modulation in inflammatory conditions, and cardiovascular effects rather than sarcopenia.\n\n## What people say on Reddit\nAnecdotal reports mention VIP in contexts of chronic inflammation, ME/CFS recovery, or training pumps via vasodilation, with some users pairing it with other compounds for muscle-related fatigue or recovery. Posts note patience required for effects and discuss it alongside immune or gut issues rather than direct muscle building. No widespread claims of dramatic muscle gain from VIP alone surface in searches; discussions remain exploratory and tied to broader health stacks.\n\n## What people say on X\nPublic posts on X show minimal specific discussion of VIP for muscle loss. Scattered mentions cover its general vasodilatory or anti-inflammatory properties, but no detailed user experiences or before-after reports tied to sarcopenia or atrophy appear in recent searches.\n\n## What we do not know\nHuman trials measuring muscle mass, strength, or function after VIP administration are absent. Long-term effects on lean mass preservation, optimal delivery methods, and interactions with exercise or nutrition remain untested in people. Whether VIP deficiency or excess correlates with sarcopenia progression in humans is unknown. Translation from rat disuse or ischemia models to human age-related or disease-driven muscle loss has not been validated.\n\n## Safety and limits\nVIP research in humans centers on its endogenous roles and short-term physiological effects; no dedicated safety database for repeated use in muscle loss contexts exists. Animal data show receptor-specific actions without broad toxicity signals in the cited studies, but individual responses vary. Evidence grading places all muscle-related findings in the preclinical tier, with anecdotal reports at the lowest tier. Always consult primary sources and professionals for personal decisions.","claims":[{"id":"c1","text":"Activation of VPAC2 receptors with VIP agonists reduced loss of skeletal muscle mass and force in rodent disuse models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Direct link to muscle preservation mechanism in lab setting.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"VIP administration at reperfusion onset increased contractile force and tissue oxygenation in ischemic-reperfused rat skeletal muscle.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Shows potential repair support in ischemia model.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"VIP knockout mice had lower body weight, lower fat mass, and increased lean mass percentage.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Indicates endogenous VIP role in body composition.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No human clinical trials test VIP for muscle loss or sarcopenia.","section":"What we do not know","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Clarifies evidence gap for readers.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users discuss VIP anecdotally for inflammation recovery or training pumps but not direct muscle gain.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s5"],"source_status":"sourced","why_material":"Separates user reports from data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:28:04.823Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/15649881/","title":"Activation of the vasoactive intestinal peptide 2 receptor modulates skeletal muscle mass and force","quote":"activation of VPAC2R, but not VPAC1R, reduced the loss of skeletal muscle mass and force during conditions of skeletal muscle disuse","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/9149300/","title":"Ischemic-reperfused rat skeletal muscle: the effect of vasoactive intestinal peptide","quote":"VIP administration at the onset of reperfusion significantly increased skeletal muscle contractile force and tissue oxygenation even higher than baseline","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/27535909/","title":"Vasoactive intestinal peptide-deficient mice show altered body composition","quote":"VIP−/− mice showed a lower body weight and fat mass and an increased lean mass","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6743256/","title":"Recent advances in vasoactive intestinal peptide physiology","quote":"VIP has multiple physiological and pathological effects","link_status":"ok","quote_status":"unverified"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/Biohack_Blueprint/comments/1u31ihv/the_peptide_nobody_talks_about_but_everyone/","title":"The peptide nobody talks about but everyone should: VIP","quote":"Mold illness and chronic inflammation does not get the same hype as fat loss or muscle growth. Two, VIP requires patience.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":14739,"tokens_out":2818,"cost":0.02546875,"prev_hash":"genesis","hash":"ab3c7fcfa3c02e16ee2de137171e857d44cceeafae49b734f25be3c8d114cc04"}],"provenance":[{"ts":"2026-06-29T22:28:05.298Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Vip for Muscle Loss\nSlug: vip-muscle-loss\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"vip\",\"name\":\"VIP\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"vip\",\"name\":\"VIP\",\"section_title\":\"Why VIP might help you\",\"layer\":\"immune / autonomic\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **VIP** → immune / autonomic\",\"section_headings\":[\"What's breaking down\",\"Why VIP might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains / drug_chains.\",\"weight","response":"{\n  \"slug\": \"vip-muscle-loss\",\n  \"title\": \"VIP for Muscle Loss: Preclinical Signals on Vasoactive Intestinal Peptide\",\n  \"body\": \"## What's breaking down\\nMuscle loss, or atrophy, occurs when breakdown outruns repair in skeletal muscle tissue. Layers include disuse from reduced activity, age-related sarcopenia with declining anabolic signals, inflammation that promotes protein breakdown via pathways like MuRF1, and impaired blood flow or oxygenation that limits nutrient delivery and waste removal. In disuse or ischemia models, contractile force drops as muscle fibers shrink. VIP sits in the immune and autonomic layer because it modulates inflammation and smooth muscle tone in vessels, potentially supporting repair signals rather than suppressing symptoms directly.\\n\\n## Why VIP might help you\\nIf your muscle loss involves an immune or autonomic component, such as chronic low-grade inflammation accelerating protein breakdown or autonomic imbalance affecting blood flow, VIP is discussed for its studied effects on tissue repair pathways. Step one: VIP activates VPAC2 receptors, which in lab models reduced skeletal muscle mass loss during disuse. Step two: This receptor activation preserved force generation, pointing to a direct influence on muscle maintenance rather than masking fatigue. Step three: In reperfusion settings after ischemia, VIP raised contractile force and tissue oxygen levels above baseline in rat muscle. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain. If autonomic regulation of blood vessels limits delivery during recovery, VIP's vasodilatory actions could fit there too.\\n\\n## How these fit together\\nSingle-compound focus — VIP targets the immune/autonomic layer. If your profile includes other degeneration layers like mitochondrial decline or hormonal shifts, this peptide addresses only the immune/autonomic slice without overlapping other mechanisms.\\n\\n## What t","tokens_in":14739,"tokens_out":2818,"cost":0,"prev":"genesis","hash":"51f30a41dda599e0554f83234ddc244f754f4b3203859afc044bff5cee47c01e"},{"ts":"2026-07-17T02:43:25.271Z","model":"owner","action":"voxel_divide","prompt":"","input":"vip-muscle-loss","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"51f30a41dda599e0554f83234ddc244f754f4b3203859afc044bff5cee47c01e","hash":"bf5b64df9799413c34643e9172e1586e7f01272be66e3a35710a6938096f8366"}],"energy":{"passes":2,"tokens_in":14739,"tokens_out":2818,"tokens_total":17557,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"bf5b64df9799413c34643e9172e1586e7f01272be66e3a35710a6938096f8366"},"posted_at":"2026-06-29T21:33:50.979Z","created_at":"2026-06-29T21:33:50.979Z","updated_at":"2026-07-17T02:43:25.271Z","machine":{"shape":"article.machine/v1","slug":"vip-muscle-loss","kind":"article","read":{"human":"https://miscsubjects.com/a/vip-muscle-loss","json":"https://miscsubjects.com/api/articles/vip-muscle-loss","bundle":"https://miscsubjects.com/api/articles/vip-muscle-loss/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":5,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/vip-muscle-loss/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=vip-muscle-loss","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-muscle-loss\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-muscle-loss\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/vip-muscle-loss/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"vip-muscle-loss\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/vip-muscle-loss | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/vip-muscle-loss","json":"/api/articles/vip-muscle-loss","markdown":"/api/articles/vip-muscle-loss/bundle?format=markdown","skill":"/api/articles/vip-muscle-loss/skill","topology":"/api/articles/vip-muscle-loss/topology","versions":"/api/articles/vip-muscle-loss/revisions","invocations":"/api/articles/vip-muscle-loss/invocations"},"editorial_review":null,"editorial_audit":{"slug":"vip-muscle-loss","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"fc4921a48d6647a6f29e9a556778f081936aa5e6c2d65d0ed4a300ad2a8a18ec"}}}